SCHEMBL22169201

SCHEMBL22169201

COc1ccccc1C(N)Nc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
ACHE P22303 1/20 0.44
CA12 O43570 1/20 0.43
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
ALDH1A1 P00352 5/20 0.41
ADRA2B P18089 1/20 0.41
PTGS1 P23219 1/20 0.41
MAPT P10636 2/20 0.40
MAPK1 P28482 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KCNK3 O14649 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20261118 0.88 CA1 (0.41) IDO1TDO2CA1CA2ACHE
SCHEMBL20261098 0.88 ALDH1A1 (0.50) CA1CA2ACHETDP1ALDH1A1
SCHEMBL20260870 0.82 IDO1 (0.41) IDO1TDO2CA1CA2ACHE
SCHEMBL10933460 0.79 CA1 (0.53) IDO1TDO2CA1CA2ACHE
SCHEMBL20169405 0.79 SLC6A2 (0.37) IDO1TDO2CA1CA2ACHE
SCHEMBL24017065 0.73 CA1 (0.57) IDO1TDO2CA1CA2ACHE
SCHEMBL15136753 0.73 CA1 (0.57) IDO1TDO2CA1CA2ACHE
SCHEMBL5188514 0.73 CA1 (0.57) IDO1TDO2CA1CA2ACHE
SCHEMBL20261094 0.72 KDM4E (0.51) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL21377269 0.71 CA1 (0.55) IDO1TDO2CA1CA2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703746-B2 Mutant IDH1 inhibitors useful for treating cancer THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10703746-B2 Mutant IDH1 inhibitors useful for treating cancer IDH1, IDH3B, IDH3A IDO1 2761/4885TDO2 3700/4885CA1 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.